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Abstract
Background: Australia uses a protocol combining human rabies immunoglobulin (HRIG) and rabies vaccine for post-
exposure prophylaxis (PEP) of rabies and Australian bat lyssavirus (ABLV), with the aim of achieving an antibody titre of
$0.5 IU/ml, as per World Health Organization (WHO) guidelines, as soon as possible.
Methodology/Principal Findings: We present the course of PEP administration and serological testing for four men with
complex requirements. Following dog bites in Thailand, two men (62 years old, 25 years old) received no HRIG and had
delayed vaccine courses: 23 days between dose two and three, and 18 days between dose one and two, respectively. Both
seroconverted following dose four. Another 62-year-old male, who was HIV-positive (normal CD4 count), also suffered a dog
bite and had delayed care receiving IM rabies vaccine on days six and nine in Thailand. Back in Australia, he received three
single and one double dose IM vaccines followed by another double dose of vaccine, delivered intradermally and
subcutaneously, before seroconverting. A 23-year-old male with a history of allergies received simultaneous HRIG and
vaccine following potential ABLV exposure, and developed rash, facial oedema and throat tingling, which was treated with a
parenteral antihistamine and tapering dose of steroids. Serology showed he seroconverted following dose four.
Conclusions/Significance: These cases show that PEP can be complicated by exposures in tourist settings where reliable
prophylaxis may not be available, where treatment is delayed or deviates from World Health Organization
recommendations. Due to the potentially short incubation time of rabies/ABLV, timely prophylaxis after a potential
exposure is needed to ensure a prompt and adequate immune response, particularly in patients who are immune-
suppressed or who have not received HRIG. Serology should be used to confirm an adequate response to PEP when
treatment is delayed or where a concurrent immunosuppressing medical condition or therapy exists.
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Introduction
Without appropriate management, infection with rabies virus or
with Australian bat lyssavirus can lead to progressive, fatal
neurologic illness. Whilst Australia is free of classical rabies,
Australian bat lyssavirus (ABLV) is endemic in local bat
populations [1]. Further, Australians are taking increasing
numbers of short, return international trips annually, including
to regional destinations where rabies is endemic. Many – 64 of 65
individuals requiring post exposure prophylaxis (PEP) in a recent
Australian paper [2] – travel without pre-exposure rabies
prophylaxis.
National guidelines for PEP of rabies and ABLV, using human
rabies immunoglobulin (HRIG) and rabies vaccine, are used in
Australia [3,4]. Reported local exposures to lyssaviruses managed
in Queensland are assessed in conjunction with the local Public
Health Unit (PHU). The aim of post-exposure vaccination is to
achieve an antibody titre of $0.5 IU/mL, as per World Health
Organization (WHO) guidelines [5], as quickly as possible. In line
with the United States [6], Australia moved from a five dose to a
four dose standard PEP protocol in November 2010 [7]. Current
PEP guidelines for both potential rabies or ABLV contact require
that healthy individuals without previous rabies vaccination
receive four vaccine doses on days 0, 3, 7, and 14 after exposure,
with a fifth dose recommended (day 28) only in the case of
immune impairment (through disease or treatment) [4]. Patients
who have not undergone pre-exposure prophylaxis receive HRIG
as part of PEP to provide early protection against migration of the
virus to the central nervous system, until a protective vaccine-
induced titre is achieved [8]; usually seen by day 14 [9]. For
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patients who have received previous rabies vaccination, HRIG is
not required and only two doses of vaccine are given on days 0 and
3 [3].
Once commenced, every effort should be made to comply with
dosing and timing for PEP schedules, including both HRIG and
vaccine. Whilst short interruptions of some days in receiving
scheduled doses are generally not of concern, the impact of longer
delays of weeks is not known [10]. In these situations, serological
testing, to monitor the immune response, taken seven to 14 days
following the final vaccine dose in the series, has been
recommended [11]. The Australian Immunisation Handbook
states that confirmatory serology is not routinely necessary, but
should be done two to three weeks following pre-exposure
prophylaxis in immunosuppressed patients at risk of exposure to
ABLV or rabies, and at two to four weeks following PEP in
immunosuppressed patients after the recommended fifth dose
given at day 28 [3].
ABLV was first identified in the brain of a young black flying
fox (Pteropus alecto) found in 1996 unable to fly, and subsequently
in a 1995 archived specimen from the same species [12,13].
ABLV has been identified as the cause in two human deaths,
with neither case having received PEP [14,15]. Bat ABLV
seroprevalance is low (,1%) in general surveys, but higher in
sick, injured, or rescued bats [1]. Thirty-one (5.2%) of 600 bats
submitted to Queensland Scientific Services between 1998 and
2006 were positive for ABLV by direct fluorescent antibody
testing [16]. There is no direct empiric evidence demonstrating
the effectiveness of current PEP regimens for preventing ABLV
in humans. An early study showed mice administered a variety
of commercial animal and human rabies vaccines were
uniformly protected against intracerebral ABLV challenge
[13]. A 2005 study showed 15 of 19 mice vaccinated twice via
the intraperitoneal route using a human diploid cell vaccine
(HDCV) survived peripheral ABLV exposure, and 10 of 20
survived intracranial exposure [17]. Whilst somewhat reassur-
ing, there are to date no published effectiveness or serology
reports on individuals who have received PEP in Australia for
potential ABLV exposure.
When potential rabies exposure occurs overseas, the traveller
may return home having had an altered or delayed PEP course or
not having commenced treatment [2]. Those with a pre-existing
medical condition or using medication that results in immuno-
suppression may also require monitoring of PEP response. Here
we present four cases with potential exposure to rabies or ABLV
between 2009 and 2011 where treatment deviated from standard
recommendations or occurred with concurrent immunosuppres-
sion.
Methods
One potential ABLV and three rabies exposures, non-standard
in nature, were referred to Brisbane North PHU for public health
physician advice. In this case series, we report PEP schedules and
serological responses (Table 1). Vaccination date refers to the
number of days post exposure, day 0 being the date of injury/
exposure.
Serology specimens were tested by Queensland Health using an
ELISA assay, Platelia Rabies II kit (Bio-Rad, Hercules, California,
USA), according to manufacturer’s guidelines. This assay has very
high agreement for detecting total anti-rabies virus glycoprotein
antibodies compared to the WHO-recommended standard [18].
Results are expressed in equivalent units per millilitre (EU/mL),
which correlate with international units (IU/mL): a value
$0.50 EU/mL represents seroconversion [18].
In this case series, serum specimens were taken from patients to
test for rabies antibodies. Oral informed consent, as opposed to
written consent, was provided by patients for these procedures as
they were part of routine clinical care. This case series was
assembled in retrospect by the physicians who participated in the
management of these patients. As such, none of the interventions
or management were part of a pre-designed research study which
would require prior ethics committee approval. We have written
consent from each of the four patients for the inclusion of their de-
identified details and clinical story in the case series.
Results
Patient 1, a 62-year-old male traveller, suffered an unprovoked
dog bite (rabies status unknown) to his thigh in Thailand in
February 2009. The wound was cleaned with soap and water for
at least five minutes. On the same day, he received an
intramuscular dose of cell-culture derived inactivated rabies
vaccine (Verorab, Sanofi Pasteur), but no HRIG.
On day 3 he received a second dose of vaccine in Thailand, but
had no further treatment until he sought medical care on day 26,
several days after returning to Australia. At this point he was given
a third dose of rabies vaccine (Rabipur, CSL Biotherapies/
Novartis Vaccines).
Rabies serology titre was collected 24 hours later: this was prior
to completion of the standard four dose course, and returned a
value of 0.31 EU/mL. After consultation with a public health
physician, he was offered a dose of rabies vaccine on the day that
the serology became available (day 30), a further dose of rabies
vaccine on day 33, with repeat serology and a final dose of rabies
vaccine on day 40. Serology collected on day 33 was 1.99 EU/
mL. This gentleman received a sixth dose of vaccine on day 40,
despite having adequate immunity on day 33 and not in keeping
with the five-vaccine protocol in use at the time [3]. The patient
remains well.
Patient 2, a 25-year-old male, was bitten on the left ring finger
by a stray puppy (rabies status unknown) in Thailand in January
2010. The wound was cleaned with soap and water for at least five
minutes. He received an intramuscular dose of rabies vaccine in
Author Summary
In Australia, the administration of rabies post-exposure
prophylaxis (PEP) occurs for potentially exposed returned
travellers from endemic regions or for potential local
exposure to Australian Bat Lyssavirus. For Australian
tourists, delays in commencing PEP or not receiving HRIG
or all recommended doses of vaccine are common. We
report a case series where serology provided information
in four patients with delayed, incomplete, or complicated
PEP treatment. Three of these patients reported a dog bite
in Thailand and the fourth was scratched by a bat and had
bat urine enter his eye in Australia. Management was
complicated by lack of HRIG administration, delays in the
recommended timeframe for receipt of vaccine doses, and
immunosuppression caused by co-administration of ste-
roids and by HIV infection with a normal CD4 count. All
patients seroconverted but this was delayed in some cases,
and in the HIV-positive subject required a double dose of
vaccine delivered intradermally and subcutaneously. In
complex or non-standard PEP delivery, including delayed
treatment and immunosuppression due to steroid treat-
ment, HIV or another immunosuppressing medical condi-
tion, serology can be used to guide further treatment and
should be used to confirm seroconversion.
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Thailand on the same day, but no HRIG. Shortly afterwards, he
returned to Australia but did not seek further treatment until day
18. His general practitioner contacted the local PHU and was
asked to perform rabies serology prior to giving two doses of
intramuscular rabies vaccine simultaneously, meaning both testing
and treatment were not consistent with standard recommenda-
tions. The rabies titre result was 0.38 EU/mL. Dose four of rabies
vaccine was given and further serology performed (day 22) which
gave a titre of 0.44 EU/mL. Further doses of rabies vaccine were
given on days 29 and 36. Repeat serology (day 29, not available on
day 36) showed a rabies titre of 2.17 EU/mL, and the patient
remains well.
Patient 3, a 62-year-old male, suffered an unprovoked dog bite
(rabies status unknown) on the back of his left calf on a Thai beach
in October 2010. The patient did not report wound cleaning. The
patient was HIV-positive and had non-insulin dependent diabetes
mellitus. His most recent CD4 count, taken approximately six
months earlier, was 560/mL (within normal limits). The patient
sought care in Thailand six days after the event, where he was
given a dose of rabies vaccine (Verorab) and HRIG, and received
a second dose of vaccine at the same clinic three days later. On his
return to Australia, he presented to his local emergency
department (ED) on day 14 where he was given an intramuscular
dose of vaccine (Rabipur). He had further doses on days 20 and
34. In view of his HIV status, rabies serology was performed on
day 49, which showed a sub-therapeutic titre of ,0.12 EU/mL.
At this stage, in consultation with the PHU, an infectious
diseases physician and a HIV specialist, he was given a double
dose of intramuscular Rabipur immediately (day 63) and serology
was repeated four weeks later (titre ,0.12 EU/mL).
On day 161 a double dose of vaccine (HDCV, Sanofi Pasteur)
was given intradermally and subcutaneously (relative volumes
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given intradermally and subcutaneously not available from clinical
notes). Serology performed two weeks later provided a titre of
1.39 EU/mL. The patient remains well.
Patient 4, a 23-year-old male with a medical history that
included eczema, asthma, and allergies (eggs, dairy products, some
food colourings), was scratched on the back of his neck by a bat
while standing under a tree in Brisbane, Queensland, in April
2010. Bat urine also entered his eye. The patient did not report
wound cleaning. The bat flew away and was unavailable for
identification and ABLV testing. He attended the local ED a few
hours after injury, and was advised at that time to return the next
morning. HRIG and vaccination (Rabipur) were administered
simultaneously the following day, and ten minutes later he
developed a generalised rash, facial oedema and tingling in his
throat. He was treated for urticaria and allergic angio-oedema
with prednisolone (50 mg p.o), promethazine (25 mg IM), and
ranitidine (300 mg p.o.). He was discharged on the same day with
a prescription for two further daily doses of 50 mg prednisolone.
After consultation between ED and PHU, the remaining doses of
rabies vaccine were given in ED. In light of the patient’s egg
allergy, the brand of vaccine was changed to an inactivated rabies
vaccine which does not contain traces of egg protein (HDCV,
Sanofi Pasteur), for doses on days 4, 8, 18, and 32. Because
steroids were co-administered, serology was performed to monitor
rabies antibody titres. On days 8 and 18, his titre was 0.16 EU/
mL, but had increased to 3.03 EU/mL on day 32. A fifth dose of
vaccine was administered to this case in keeping with national
guidelines, requiring a five dose PEP regimen following ABLV
exposure, at the time [3]. The patient remains well.
Discussion
Failure of rabies PEP regime has been documented [19,20], but
is uncommon if properly administered [21]. As illustrated by our
case series, PEP is often complicated by exposures in tourist
settings where reliable prophylaxis may not be available, treatment
being delayed until return home, or where variations in
administration exist [2,8]. Delays in starting PEP and not receiving
the recommended full course of HRIG and vaccines is common in
Australian travellers [2]. These cases also illustrate the importance
of timely prophylaxis after a potential rabies/ABLV exposure to
ensure an adequate immune response, particularly in the context
of medical conditions or treatment that may result in immuno-
suppression.
None of the individuals in this case series had previously
received rabies vaccine. Pre-exposure prophylaxis is recommended
for Australian travellers spending more than a month, or working
with mammals, in a rabies-endemic region; those likely to receive
bites or scratches from Australian bats; or are laboratory personnel
working with live lyssaviruses [3]. A recent Australian study
questioned the adequacy of these recommendations given that, in
their case series, most injuries occurred within 30 days of arrival in
a rabies-endemic region, most were injured whilst participating in
common tourist activities, more than a third did not initiate
contact with animals, and the most common injury sites were
hands and fingers – high risk sites for rabies transmission due to
rich nerve supply [2]. These findings are reinforced by the pattern
of exposure in the three subjects in our case series who were bitten
by a dog in Thailand. The authors recommended all travellers to
rabies endemic regions be counselled about high-risk behaviours,
avoiding animal bites, and be offered pre-exposure vaccination
[2].
In each of the cases described, there was a delay between injury
and seroconversion. This is particularly important given the
incubation period for rabies/ABLV may be as short as 2 weeks, or,
rarely, several days [22,23]. Most rabies deaths occur when there
is deviation from WHO PEP guidelines [21], reinforcing the
importance of monitoring the serological response to treatment in
certain patients, such as those presented above. Patient 1 and 2
received no HRIG as part of their PEP. This is concerning, as
rabies has been documented where HRIG has not been infiltrated
into the wounds of exposed patients [24,25]. Failure to access
HRIG whilst overseas, particularly in developing countries,
appears to be a common problem, even following severe hand
or facial injuries [2,26,27]. Given the recent shift to a standard
four dose PEP schedule, it is encouraging to note that all but one
case seroconverted after four doses of rabies vaccine, despite
disruptions to recommended timing.
There were a number of deviations from standard testing and
treatment in our cases. These testing deviations in this case series
have provided serological data at non-standard time points. Both
patient 1 and 2 had serology collected before receiving four doses
of vaccine, and, as may be anticipated, had not seroconverted.
However, these assays showed the immune response in both
patients had risen above baseline. Patient 2 received a double dose
of vaccine following a prolonged delay after dose 1, and both
patients 1 and 2 received six doses of vaccine in total. These events
are likely an outcome of excessive caution and confusion that
surrounds prolonged deviations from recommended PEP sched-
ules. The delay in patient 3 between his last intramuscular dose
(day 63) and effective intradermal/subcutaneous dosing (day 161)
was due to discussions about the most appropriate management
plan, in the absence of strong evidence, and communicating this
with the patient. Rabies is an almost invariably fatal disease
meaning uncertainty about PEP implementation generates much
anxiety for both patients and clinicians. Deviating from existing
guidelines, particularly with early serology or extra vaccine doses,
is likely to be inefficient and potentially confusing for the patient
and others involved in their care. Every effort should be made to
comply with recommended testing and treatment protocols
following potential ABLV- or rabies-prone injury.
Patient 4 in our series received short course oral steroids
immediately following his first vaccine, and had a protective titre
demonstrated on day 32, 14 days after his fourth dose. Of note,
short-course oral corticosteroids equivalent to a prednisolone dose
of less than 20 mg/day are not thought to interfere with the
immune response to vaccination [28]. This patient took 50 mg/
day for three days, but had adequate seroconversion two weeks
after dose 4.
Failure of pre-exposure prophylaxis and PEP has been
documented in individuals with immune deficiency secondary to
HIV infection [29,30]. Patient 3 had well controlled HIV, but had
not mounted a protective antibody response 161 days after seven
IM doses, despite a recent normal CD4 count. Interestingly, he
developed a titre of 1.39 EU/mL shortly after a double dose of
HDCV vaccine, given in part intradermally and subcutaneously.
There are very limited data about using intradermal rabies vaccine
in HIV-infected patients as PEP [31], and whether it may be more
effective at producing an immune response in HIV-infected
patients than IM vaccine remains unclear. Care is needed in
assessing HIV patients after potential rabies exposure even when
immunosupression is thought to be mild. Further clinical trials are
required to identify optimal PEP regimens in HIV-infected patient
groups with varying immunosuppression.
In conclusion, clinicians should be aware that a delay between
injury/exposure and PEP administration, schedule interruption,
or complicating immunosuppression may inhibit or delay
seroconversion. Due to the potentially short incubation period of
Serology Use during Rabies/ABLV PEP
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rabies/ABLV, particular care must be taken in such patients
where HRIG has not been administered. In cases with delayed
treatment, complicating medical history, or concurrent steroid or
other immunosuppressing therapy or medical condition, serology
should be used, where available, to monitor the response to PEP
and confirm serconversion has occurred.
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